Page 7 - CUA 2020_Onco_Bladder
P. 7
Unmoderated Posters 2: Uro-Oncology, Pediatrics, Sexual Dysfunction, Transplant
UP-2.5. Table 1. Demographic and clinical factor comparison table for recurrent UTIs confirmed by 3 or more positive
urine cultures in the previous year
Total No Yes p
N=124 n=94 n=30
Age, mean ± SD 37.3±13.9 38.4±14.1 34.0±13.0 0.142
Sex (%)
Female 17 (13.7%) 10 (10.6%) 7 (23.3%) 0.123
Male 107 (86.3%) 84 (89.4%) 23 (76.7%)
BMI, mean ± SD 25.7±6.3 25.3±6.1 26.7±6.8 0.336
Race (%)
Black 34 (27.4%) 21 (22.3%) 13 (43.3%) 0.033
Other 12 (9.7%) 8 (8.5%) 4 (13.3%)
White 78 (62.9%) 65 (69.1%) 13 (43.3%)
SCI level of injury, n
Cervical 42 (33.9%) 32 (34.0%) 10 (33.3%) 1.000
Thoracic 72 (58.1%) 54 (57.4%) 18 (60.0%)
Lumbar 10 (8.1%) 8 (8.5%) 2 (6.7%)
Years since SCI, mean ± SD 5.0±6.7 5.6±7.0 3.1±5.2 0.018
History of diabetes mellitus (%) 6 (4.8%) 4 (4.3%) 2 (6.7%) 0.631
History of decubitus ulcers (%) 26 (21.0%) 20 (21.3%) 6 (20.0%) 0.881
Bladder stone(s) present (%) 8 (6.5%) 7 (7.4%) 1 (3.3%) 0.678
Renal stone(s) present (%) 15 (12.1%) 13 (13.8%) 2 (6.7%) 0.358
Hydronephrosis present (%) 4 (3.2%) 2 (2.1%) 2 (6.7%) 0.246
Vesicoureteral reflux present (%) 4 (3.2%) 4 (4.3%) 0 (0.0%) 0.571
Reports urinary incontinence (%) 80 (64.5%) 59 (62.8%) 21 (70.0%) 0.471
Anticholinergic medication use (%) 68 (54.8%) 51 (54.3%) 17 (56.7%) 0.837
Antibiotic prophylaxis use (%) 9 (7.3%) 7 (7.4%) 2 (6.7%) 1.000
DO present (%) 88 (71.0%) 68 (72.3%) 20 (66.7%) 0.551
Volume at first DO , median (range) 262.0 (38–850) 275.0 (38–850) 225.0 (56–550) 0.287
†
Max Pdet during DO , median (range) 50.0 (9–180) 50.0 (9–180) 55.0 (25–149) 0.240
‡
Cystometric capacity, median (range) 475.0 (35–1346) 486.5 (73–1346) 395.0 (35–1225) 0.424
End fill detrusor pressure, median (range) 7.5 (1–74) 7.5 (1–74) 7.5 (1–46) 0.699
Compliance, median (range) 44.7 (1.1–475.0) 42.4 (4.5–475.0) 50.0 (1.1–375.0) 0.641
Number of UTI in previous year*, mean ± SD 1.6±1.7 0.8±0.8 4.1±1.7 0.000
† Volume at first DO corresponds to the infused volume during UDS at which the first uninhibited detrusor contraction occurred. ‡ Max Pdet during DO corresponds to the maximum detrusor
pressure obtained during an uninhibited detrusor contraction. This was run as a continuous variable. *Number of UTI in previous year corresponds to the number of culture-proven infec-
tions within the previous year leading up to their presentation to urology.
UP-2.6 Introduction: Surgical interventions continue to be the mainstay treatment
®
The Contino urethral insert in the treatment of male stress for men with stress urinary incontinence (SUI). For patients with comorbidi-
urinary incontinence ties that preclude them from surgery or those that are unwilling to undergo
2
Dean S. Elterman , Richard W. Casey , Thomas J. De los Reyes , Michael invasive therapy, non-surgical options are limited to external compression or
1
1
Holloway 3 collection devices coupled with behavioral modifications. These are often not
®
2
1 Urology, University Health Network, Toronto, ON, Canada; The Fe/ satisfactory in controlling leakage. The Contino is a self-administered device
3
Male Health Centres, Oakville, ON, Canada; Life360 Innovations Inc., placed into the distal urethra to inhibit urine flow, which is then removed
Vancouver, BC, Canada prior to urination. This prospective, non-randomized, single-arm trial was
®
Support: Life360 Innovations Inc. sponsored this study used to assess the efficacy of the Contino device in treating male SUI.
UP-2.6. Table 1. ICIQ-SF data summaries by day
Day n Mean SD MIN Median MAX Q1 Q3 IQR
Baseline 26 16.5 3.7 9 17 21 14 19.8 5.8
Interim 17 13.8 5.4 3 15 21 9 18 9
End 13 12.2 5.5 5 12 21 7 17 10
CUAJ • June 2020 • Volume 14, Issue 6(Suppl2) S59